Rationale and Design of a Multicenter, Randomized Phase II Trial of Durvalumab with or Without Multitarget Tyrosine Kinase Inhibitor As Maintenance Treatment in Extensive‐stage Small‐cell Lung Cancer Patients (DURABLE Study)
CLINICAL RESPIRATORY JOURNAL（2023）
Key words
anti-angiogenesis,check-point inhibitors,ES-SCLC,maintenance treatment
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined